Loading...
Loading...
REVBW| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 7,968.9M |
| Operating I/L | -7,968.9M |
| Other Income/Expense | -7,056.3M |
| Interest Income | 0.0M |
| Pretax | -15,025.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -15,025.2M |
Revelation Biosciences, Inc. is a clinical stage biopharmaceutical company specializing in immunologic-based therapeutics and diagnostics. Its lead product, REVTx-99, is an intranasal immunomodulator designed to prevent or treat infections caused by various respiratory viruses, including SARS-CoV-2 and its variants, influenza, parainfluenza, rhinovirus, and RSV. The company also develops REVTx-200, an intranasal immunomodulator adjunct for use with intramuscular vaccinations, and REVDx-501, a rapid home use diagnostic for respiratory viral infections. These products form the core of the company's revenue stream, focusing on addressing respiratory infections and related conditions.
